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ABSTRACT
Despite multimodal treatment, long term outcome for patients with Ewing 
sarcoma is still poor. The second “European interdisciplinary Ewing sarcoma research 
summit” assembled a large group of scientific experts in the field to discuss their latest 
unpublished findings on the way to the identification of novel therapeutic targets and 
strategies. Ewing sarcoma is characterized by a quiet genome with presence of an 
EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNA-
sequencing of recently described Ewing-like sarcomas with variant translocations 
identified them as biologically distinct diseases. Various presentations adressed 
mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were 
presented shedding light on the molecular underpinnings of genetic permissiveness 
to this disease uncovering interaction of EWS-FLI1 with recently discovered 
susceptibility loci. Epigenetic context as a consequence of the interaction between the 
oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as 
dominant theme in the discussion of the molecular pathogenesis and inter- and intra-
tumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models 
faithfully recapitulating the human disease. The problem of preclinical development 
of biologically targeted therapeutics was discussed and promising perspectives were 
offered from the study of novel in vitro models. Finally, it was concluded that in order 
to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing 
sarcoma, the community needs a platform to maintain knowledge of unpublished 
results, systems and models used in drug testing and to continue the open dialogue 
initiated at the first two Ewing sarcoma summits.
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INTRODUCTION
Ewing sarcoma is a rare, aggressive cancer of bone 
and soft tissues that presents most frequently in children 
and young adults. Progress in Ewing sarcoma therapy has 
reached a plateau with long-term overall survival rates 
less than 30% for patients with disseminated disease 
and 65-75% for patients who present without clinically 
overt metastases at diagnosis [1]. Using conventional 
multimodal treatment regimens, only minor improvements 
in outcome have been achieved during the last 30 years 
[2]. Therefore, more efficient and specifically targeted 
approaches are urgently required to combat this deadly 
disease. Such novel therapeutic strategies are expected 
to arise from a deeper biological understanding of the 
pathogenic mechanisms underlying the development, 
immune escape and metastatic spread of Ewing sarcoma. 
International Ewing sarcoma research, however, is 
fragmented and progress is slow due to the rarity of 
the disease (approximately 3 cases/million/year [3]). 
Two European framework program 7 (FP7) funded 
collaborative initiatives therefore put on their agenda 
activities to overcome this apparent bottleneck, although 
by different approaches. The research project ASSET 
(“Assessing and Striking the Sensitivities of Embryonal 
Tumors”) follows a multi-disciplinary systems biology 
approach to identify vulnerabilities of the disease. The 
“European Network for Cancer research in Children 
and Adolescents” (ENCCA) facilitates and structures 
networking activities for prioritization of, access to and 
clinical research on innovative, biologically targeted drugs 
for the treatment of childhood cancer. However, regular 
exchange of knowledge and networking is required beyond 
European borders and beyond the tightly defined agenda 
of such projects to avoid redundancy and generate synergy 
in Ewing sarcoma research. In June 2015, four years after 
the first ENCCA funded Ewing sarcoma meeting [4] and 
jointly supported by ENCCA and ASSET, the “Second 
European Interdisciplinary Ewing Sarcoma Research 
Summit” assembled 77 researchers from Europe, Japan, 
the US and Canada to share exclusively unpublished 
results and to discuss future research directions and 
opportunities for clinical translation (Suppl. Table 1 for 
list of participants). It was the largest purely scientific 
Ewing sarcoma convention so far. Maybe it was the spirit 
of the venue at Institute Curie in Paris, where the EWSR1-
FLI1 fusion gene was discovered as the defining marker 
and driver of the disease almost 25 years ago, combined 
with the unique meeting format, that made it highly 
successful in bringing together colleagues and competitors 
in the field, fostering trustful exchange, open discussion, 
and the initiation of new promising collaborations. This 
review summarizes some exciting new insights into 
Ewing sarcoma biology presented at this meeting (Figure 
1). Since speakers frequently used metaphors in their 
presentations, the chapters of this review are named 
accordingly (Figure 2). 
THE MONSTER
In our nightmares and in horror movies, it is the 
unknown, the mysterious that threatens us in the shape 
of a dangerous monster. Ewing sarcoma remains such 
a monster, a “genetically engineered monster” with 
the EWSR1-ETS gene fusion as the major driver of its 
nefarious activities, as Paul Meltzer pointed out while 
introducing the topic of “Spatial and temporal genetic and 
non-genetic diversity of Ewing sarcoma” (Table 1). From 
recent sequencing studies it has become clear that with the 
exception of the well-known EWSR1-ETS gene fusions, 
which drive a complex tumor specific transcriptional 
program, the Ewing sarcoma genome is relatively quiet [5-
9]. Franck Tirode provided an overview on the molecular 
heterogeneity of Ewing and Ewing-like tumors in a cohort 
of 130 sarcomas. By RNA sequencing he demonstrated 
that tumors with FET-ETS gene fusions involving EWSR1 
or FUS with members of the ERG (FLI1, ERG) or PEA3 
(ETV1, ETV4) subfamily of ETS transcription factor genes 
cluster tightly together in a homogenous group, separate 
from Ewing-like sarcomas with EWSR1 fusions to non-
ETS genes (i.e. NFATC, POU5F1, SMARCA5) and from 
those harboring the recently described BCOR-CCNB3 or 
CIC-DUX4 gene fusions. 
Some of the mystery behind Ewing sarcoma 
pathogenesis and the inter-patient heterogeneity in its 
response to treatment may arise from non-genetic sources, 
such as the epigenome. Paul Meltzer stressed that the 
epigenetic states of cancer are generally abnormal, not 
fitting any healthy tissue, and thus, cancers deviate from 
physiologic epigenetic programs. In Ewing sarcoma, 
widespread epigenetic rewiring of gene regulatory regions 
was recently demonstrated to be induced by EWS-FLI11 
[10, 11]. Knowledge about the exact mechanisms of 
epigenetic dysregulation may provide novel therapeutic 
opportunities. Stephen Lessnick reported on the preclinical 
testing of HCI2577, a second generation lysyl specific 
demethylase (LSD1) inhibitor, which they found to 
reverse the EWS-FLI1 transcriptional signature to a large 
extent and to cause apoptosis. However, based on previous 
results of the group on the anti-tumor effects of the first 
generation inhibitor HCI2509 [12], LSD1 inhibition 
affected both EWS-FLI1 activated and repressed 
genes that are bound by the fusion oncogene, the exact 
mechanism of functional interaction between EWS-FLI1 
and LSD1 remains obscure.
Non-genetic variability may also be the basis for 
distinct treatment sensitivity. Paul Meltzer reported on 
differences in tumor transcriptomes of patients transiently 
responding or not to the R1507 IGF1R antibody in the 
SARC-011 trial. The molecular basis for resistance 
development may lie in genetic or non-genetic intra-
tumor heterogeneity. Olivier Delattre introduced single 
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cell transcriptome analysis to study variation and 
transitions in transcriptional programs in a population 
of Ewing sarcoma cells with fluctuations in EWS-FLI1 
expression. Nathan Sheffield demonstrated the power 
of reduced representation bisulfite sequencing (RRBS) 
to study cell-to-cell heterogeneity in DNA methylation 
of a tumor. Neighboring CpG sites in a given genomic 
region often show concordant methylation status, but 
Figure 1: The multiple layers of complexity in Ewing sarcoma biology and novel treatment perspectives discussed at 
the “Second Interdisciplinary Ewing Sarcoma Research Summit”.
Table 1: Genetic and non-genetic sources of inter- and intra-tumor heterogeneity in Ewing sarcoma
Genetic
Germline genetic risk (susceptibility loci on chromosomes 1, 10, 15; metastasis loci?)
Different EWSR1-transcription factor fusions
Copy number variations (i.e. gains on chromosomes 8, 12, 1q; loss at 16p)
Clonal complexity of tumor
Therapy driven mutation/selection
Non-genetic
Plasticity of tumor/tumor stem cells
Heterogenous epigenetic states (chromatin factors and DNA methylation)
RNA metabolism (splicing, editing, degradation)
Activity of non-coding RNAs (microRNAs, long noncoding RNAs, others)
Metabolism (tissue site, microenvironment, stress and therapy driven)
Proliferative states (dormancy)
Micro-environment modification of tumor cells (i.e. immune system)
Age and gender 
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the methylation of neighboring CpGs is occasionally not 
matching, leading to potentially disordered methylation 
patterns. Because each read may span several methylation 
sites and is derived from the sequencing of one DNA 
molecule, the comparison between methylation status at 
neighboring CpGs within a read can be used to assess 
intra-tumor heterogeneity. Nathan Sheffield demonstrated 
this phenomenon in a cohort of 140 Ewing sarcomas 
and normal mesenchymal stem cell samples, which are 
currently being explored for prognostic methylation 
patterns in a collaborative project between Austria, France 
and Germany. 
Comparative methylation profiling between Ewing 
sarcoma and normal tissues also has the potential to 
uncover unknown tumor specific molecular traits. Using 
the Infinium 450K methylation array to study promoter 
methylation, Oscar Tirado´s group identified Ewing 
sarcoma specific inactivation of the PTRF/Cavin-1 gene, 
which, when co-expressed with the EWS-FLI1 activated 
target gene Caveolin-1 (CAV1), induced TP53 dependent 
cell death. These results support the use of demethylating 
drugs for the treatment of Ewing sarcoma.
High-throughput sequencing technologies enable 
characterization of the genetic and epigenetic make-up and 
the transcriptional signature of tumors, and, by correlation 
analysis, how the one affects the other. Andrei Zinovyev 
described a computational method based on a Boolean 
mathematical model to predict genetic interactions and 
thus explain deviations of the phenotypic quantitative 
effect of multiple gene mutations from their simple 
additive effect as applied to Ewing sarcoma [13]. Theo 
Papamarkou discussed a novel mathematical method to 
also integrate so far poorly investigated RNA editing 
effects in gene regulatory networks based on RNA-seq 
data.
Several presentations addressed approaches to 
follow the tracks of the monster over time. Markus 
Metzler and Brian Crompton described methods for non-
invasive detection of impending relapse based on the 
high-sensitivity detection of circulating tumor DNA in the 
plasma of Ewing sarcoma patients. Long-range PCR and 
capture sequencing methods are being applied to determine 
patient-specific genomic EWSR1-FLI1 breakpoints which 
are subsequently used to detect tumor DNA shed in the 
circulation by digital PCR. Thus, Uta Dirksen presented 
first results from the “EFACT” (EWSR1-FLI1 sequence 
Figure 2: Factors involved in the pathogenesis of Ewing sarcoma. Seed (risk alleles at Ewing sarcoma susceptibility loci), 
soil (tissue microenvironment), hen (tissue of origin), rooster (developmental , epigenetic state), egg (driver mutation), monster (Ewing 
sarcoma).
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analysis from ctDNA) study ancillary to the European 
clinical Ewing sarcoma trials Ewing2008 and Ewing 2012, 
while Marc Ladanyi presented data based on the MSK-
IMPACT program at Memorial Sloan Kettering Cancer 
Center, which provided proof of principle for detection 
of circulating tumor (ct) DNA in the plasma preceding 
clinically overt relapse of Ewing sarcoma.
HEN AND EGG
While Omics technologies take a scan of Ewing 
sarcoma, the fully matured monster, and allow us to 
monitor its variability and plasticity, the egg from which 
it hatched remains unknown. Much of the difficulty 
in identifying the tissue of origin for Ewing sarcoma 
arises from the toxicity of EWSR1-ETS fusion genes to 
most cell types. This is probably the reason why most 
attempts to generate animal models of EWS-ETS driven 
oncogenesis have so far failed. The current view is that 
the disease arises from some mesenchymal or neural crest 
derived stem or progenitor cell. Erika Brunet reported that 
though it was possible to induce the EWSR1-FLI1 gene 
rearrangement in adult mesenchymal stem cells by zinc 
finger nucleases or CRISPR/Cas9 mediated gene editing, 
the gene fusion was unstable and gradually counter-
selected in this cell type. Using the latter genome editing 
approach, Marc Ladanyi also showed efficient induction 
of the EWSR1-FLI1 gene rearrangement in HEK293 cells. 
Aykut Üren summarized a plethora of mostly unpublished 
(because unsuccessful) attempts from various labs to 
generate EWS-ETS transgenic tumor models in rodents 
and fish by either conditional tissue specific activation or 
topical administration of the fusion gene. Most of them 
led to no phenotype or embryonic lethality, tissue damage 
(i.e cardiomyopathy [14]) and/or developmental defects, 
but not tumorigenesis. These studies included expression 
of the gene fusion in osteoblast precursors, limb bud 
mesenchyme, neuronal tissue, or muscle, using a variety of 
promoters to drive the gene fusion (CMV, LTR, EWSR1, 
Rosa26, Pgk, Nse, dNEFL, TRE) and Cre lines to activate 
the transgene (Runx2Cre, OsxCre, Prx1Cre, Dermo1Cre, 
P0Cre, Col1a2Cre, Sox9Cre). Given that even in humans 
Ewing sarcoma incidence varies with ethnicity (the disease 
is particularly rare in Africans), it is possible that model 
organisms are not susceptible to this disease. Aykut Üren 
discussed several potential reasons for this assumption, 
including different gene splicing patterns and variations 
in the lengths of GGAA micro satellites, two features that 
may differentially affect EWS-FLI1 function and target 
gene expression in mice and men. 
However, Richard Moriggl presented data from 
a Prx1Cre driven EWS-FLI1 mouse model established 
in his group, which implicates developmental timing of 
the gene fusion as an important factor in tumorigenesis. 
When activated (using a tamoxifen-inducible Cre 
recombinase) in a narrow time window around birth, 
EWS-FLI1 expression in the bone mesenchyme resulted 
in sarcomas that recapitulate the human Ewing sarcoma 
EWS-FLI1 transcriptional signature. Consistent with 
this finding, Takuro Nakamura described their recently 
published transplantation model of tumors arising from 
EWS-FLI1 transgenic embryonic superficial zone cells 
from the articular cartilage at an ERG and PTHLH 
expressing developmental stage [15], and compared it 
to an unpublished similarly constructed model of CIC-
DUX4 induced tumorigenesis from the same cell type. He 
demonstrated that the CIC-DUX4 gene fusion activates 
PEA3 and ERG family ETS transcription factors and, 
similar to EWS-FLI1, down-regulates apoptosis genes. 
In zebrafish, James Amatruda reported on the use 
of transgenic EWS-FLI1 zebrafish for small-molecule 
and genetic screens, and a new model of CIC-DUX4-
Ewing-like sarcomas. Wietske van der Ent discussed their 
attempts to generate a flexible transgenic zebrafish model 
of EWS-ERG induced tumorigenesis using the binary 
UAS/GAL4 system. Similar to mice, most tested fish 
tissues did not tolerate the fusion gene with one exception: 
Expression of GFP-tagged EWS-ERG in neuronal 
tissues led to developmentally impaired embryos with 
large amounts of GFP-positive transformed cells, which 
showed histological features similar to Ewing sarcoma. 
Transcriptomic and proteomic analysis of regulated gene 
expression in these embryos showed that there was an 
overlap with human and murine expression profiles linked 
to Ewing sarcoma development.
The notion that certain embryonal mesenchymal and 
neuronal tissues tolerate EWS-ETS gene expression in 
animal models, at least at defined developmental stages, is 
consistent with the current view that Ewing sarcoma arises 
from some potentially neural crest-derived mesenchymal 
or neuronal progenitor cells. Elizabeth Lawlor reviewed 
the published evidence for this hypothesis and put it into 
context with available knowledge on pluripotent adult stem 
cells. These cells express high levels of polycomb proteins 
to suppress a large number of differentiation genes. Among 
them are EZH2 and BMI-1 and, as Inmaculada Hernandez 
and Jaume Mora reported, RING1B (RNF2), which 
affects genes of heme biosynthesis, endothelial and neural 
development, and which they found to protect Ewing 
sarcoma cells from NFκB induced apoptosis through 
regulation of the sodium channel NaV1.6. Summarizing 
available evidence, Elizabeth Lawlor speculated that BMI-
1 positive cells may provide the permissive environment 
for fusion gene activity, as has previously been reported 
for E2A-PBX1 in hematopoietic stem cells [16], and more 
recently demonstrated by her own group for EWS-FLI1 in 
neural crest derived stem cells (NCSC) [17]. The chimeric 
oncogene would then perpetuate the progenitor-like state 
by hijacking the developmental transcription program. 
On the other hand, there are developmental genes 
which escape suppression by overexpressed polycomb 
proteins in Ewing sarcoma. It has previously been 
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demonstrated that posterior homeobox (HOX) cluster D 
genes are paradoxically highly expressed in this disease 
[18]. Günther Richter and Stefan Burdach studied the 
mechanism and consequences of this up-regulation. They 
presented preliminary data indicating that HOXD10,11 
and 13 genes are regulated via the EWS-FLI1 target 
DKK2, presumably involving the canonical WNT/β 
catenin pathway, to drive chondrogenic but not osteogenic 
differentiation. Knockdown of HOXD genes resulted in 
down-regulation of RUNX2, PTHLH, BGLAP, PDGF-
BB and MMP1 reducing contact independent growth and 
metastatic potential of Ewing sarcoma cells. Elizabeth 
Lawlor concluded that, when it comes to the hen and 
egg question of which is the limiting factor in Ewing 
sarcomagenesis, cell type/stage of origin or EWS-ETS 
activity, the two features are tightly intertwined and cannot 
be separated from each other.
SEED AND SOIL
In contrast to infectious diseases, where the affected 
patient´s tissues serve as host for the invading pathogens, 
cancer constitutes a host tissue in itself. It is, however, 
comprised of multiple cell types that influence each 
other, as Lee Helman pointed out in his introduction to 
the topic “Targeting the Ewing sarcoma ecosystem”. 
Tumor-microenvironment interactions occur between 
multiple host cell types. Tumor infiltrating fibroblasts, 
adipocytes and immune cells alter their metabolism to 
adapt to the tumor environment where they create an 
immunosuppressive milieu. Lee Helman referred to a study 
that demonstrated the importance of the mitochondrial 
Krebs cycle in shaping the nuclear methylome of several 
cancers [19] and speculated that metabolic adaptations 
in tumor-microenvironment interactions may affect 
the epigenome of both tumor and infiltrating host cells. 
In addition, he pointed out that genotoxic treatments 
elicit DNA damage responses in healthy tissues leading 
to inflammatory responses that affect tumor cells and 
metastases. Steve Lessnick discussed the contrasting 
effects of normoxia and hypoxia on proteolytic cleavage 
and isoform expression of neuropeptide Y (NPY) 
with opposite consequences for cell proliferation and 
apoptosis (Tilan et al. 2013). Consequently, several talks 
addressed the interaction between the seed - the molecular 
underpinnings of Ewing sarcoma, and the soil - the tumor 
microenvironment. 
Previously, the group of Franck Tirode demonstrated 
that sustained knockdown of EWS-FLI1 restores 
multipotency to Ewing sarcoma cell lines in vitro [20]. 
Expanding on this observation, Olivier Delattre reported 
that EWS-FLI1 silencing in the in vivo context of a mouse 
xenograft model resulted specifically in adipogenic 
differentiation of tumor cells. Similarly, Patrick Grohar 
observed replacement of the tumor tissue in Ewing 
sarcoma bearing mice by fat tissue of human origin upon 
treatment with PM01183, a second generation Trabectedin 
analog. This drug, which similar to UV distorts and 
breaks DNA strands, seems to inactivate EWS-FLI1 
by driving it into the nucleolus. Thus, it appears that 
the tumor microenvironment has a profound effect on 
the differentiation route of Ewing sarcoma cells upon 
inactivation of the fusion gene in vivo. However, it is not 
clear if this effect resulted from the direct differentiation 
of Ewing sarcoma cells or due to the creation of a pro-
adipogenic microenvironment.
Wnt/β-catenin signaling is one of the developmental 
pathways deregulated in Ewing sarcoma. In mesenchymal 
tumors it acts as a morphogen rather than driving 
proliferation. It has been demonstrated previously that 
activation of the Wnt pathway in Ewing sarcoma is 
potentiated by R-spondins, the ligands of the somatic 
stem cell surface receptor LGR5, which stabilizes 
β-catenin and functions as an oncogene in several human 
cancers [21]. Elizabeth Lawlor reported that while under 
standard in vitro growth conditions Wnt signaling is off 
and can only be activated upon EWS-FLI1 silencing and 
ligand addition, focal β-catenin staining is observed in 
primary tumors. Because LEF1/TCF is a transcriptional 
downstream effector of Wnt/ β-catenin signaling and its 
expression is associated with poor prognosis, Elizabeth 
Lawlor speculated about intra-tumor heterogeneity of 
EWS-FLI1 expression and the role of the tumor micro-
environment in activating Wnt/ β-catenin and its role 
in promoting tumor cell motility and metastasis. In this 
context, the applicability of the tumor stem cell model to 
Ewing sarcoma was discussed by Eberhard Korsching.
In light of recent evidence that suggests the EWS-
FLI fusion protein may act as a pioneer factor capable of 
eliciting broad sweeping epigenetic effects, novel ex vivo 
models may provide an innovative platform to determine 
how microenvironmental cues—and their downstream 
signaling cascades—contribute to and/or reinforce 
epigenetic changes linked to the aberrant EWS-FLI fusion. 
One way to study bidirectional feedback mechanisms 
that exist between Ewing sarcoma and its adjacent 
microenvironment is with ex vivo tissue engineered three-
dimensional culture models. Such a model was pioneered 
by Joseph Ludwig´s laboratory. As recently published, 
in sharp contrast to Ewing sarcoma cells cultured 
upon flat tissue culture plastic ware, cells cultured on 
biologically inert poly(ε-caprolactone) (PCL) microfiber 
scaffolds placed within a flow perfusion bioreactor were 
hypersensitive to IGF-1R targeted monoclonal antibodies, 
which represent a promising class of precision-guided 
experimental drugs currently in evaluation in early phase 
clinical trials. Intriguingly, though improved nutrient 
delivery throughout the porous scaffolds contributed to 
cell survival within this preclinical model, heightened 
sensitivity to IGF-1R antibodies seemed to be mediated 
by physiological levels of shear stress that can be precisely 
regulated experimentally [22]. Similarly, Francoise 
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Rédini used novel mineralized scaffolds to investigate 
the vicious cycle between osteoclasts, bone stromal cells/
osteoblasts and tumor cells in Ewing sarcoma progression 
by transcriptomic analysis. Results are integrated with 
differential gene expression patterns and therapy responses 
observed in patients and pre-clinical models of bone 
versus soft tissue Ewing sarcoma. Such an approach 
may also be useful to validate the potential influence of 
the stromal component on the prognostic transcriptional 
signature of Ewing sarcoma with respect to chemokine 
receptor expression CXCR7 and CXCR4 isoforms that 
differ in their affinity to antagonistic ligands CXCL12 and 
CXCL14, discussed by Karoly Szuhai. 
Tumor growth beyond the reach of existing 
vasculature triggers cellular adaptations to overcome 
limiting nutrient and oxygen delivery. In addition, 
oncogenic activation and metabolic re-programming 
elicit cell intrinsic stresses. Under these conditions, 
metabolism is re-wired to support cellular energy 
homeostasis and to supply the building blocks for biomass 
[23]. One mechanism of energy preservation is selective 
withdrawal of mRNAs from translation by storage in 
ribonucleoprotein complexes, called stress granules. Poul 
Sorensen described that under oxidative stress up to 60% 
of mRNA gets entrapped in stress granules. He recently 
reported that the RNA binding protein YB-1 translationally 
activates expression of a number of stress-responsive 
proteins including HIF1α [24], and activates translation of 
the stress granule nucleator, G3BP1 [25]. He reported on 
proteomic approaches to define the composition of YB-1 
containing stress granules, and the promising activity of 
several histone deacetylase inhibitors in preventing stress 
granule formation.
A so far unrecognized hint to a potential role of 
stress granules in the pathogenesis of Ewing sarcoma 
may arise from the functional analysis of genes in the 
vicinity of Ewing sarcoma susceptibility loci. A previously 
published genome-wide association study from the 
Delattre lab identified candidate risk loci on chromosomes 
1, 10, and 15 [26]. The chromosome 1 susceptibility SNP 
rs9430161 is located in the vicinity of TARDBP, encoding 
an RNA binding protein that is structurally similar to 
and co-localizes with FUS and EWS to stress granules. 
Heinrich Kovar now reported on preliminary results 
generated by Dave Aryee suggesting that the chromosome 
15 associated risk locus rs4924410 may affect the activity 
of a further stress granule associated protein, SRP14, via 
EWS-FLI1 dependent regulation of a novel long non-
coding (lnc)RNA. 
While these studies are still in their infancy, 
Thomas Grünewald summarized his recently completed 
study on the functional analysis of the chromosome 10 
encoded Ewing sarcoma susceptibility locus, which he 
demonstrated to affect expression of the Ewing sarcoma 
growth regulatory EGR2 gene through extension of an 
EWS-FLI1 bound enhancer-like GGAA microsatellite 
[27].
All together, these findings underline the context-
specific role of EWS-ETS proteins in giving birth to the 
monster. It is clear that dysregulation of transcriptional 
programs by EWS-ETS driven wide-spread enhancer 
reprograming and promoter deregulation is a major factor 
shaping the biological and clinical characteristics of this 
monstrous disease. At the meeting, however, some less 
well characterized EWS-ETS activities and their potential 
roles in sarcomagenesis and progression were discussed. 
Alejandro Sweet-Cordero reported that EWS-
FLI1 deregulates the expression of >300 lncRNAs, some 
directly some indirectly. He presented data on two highly 
expressed Ewing sarcoma specific, EWS-FLI1 regulated 
lncRNAs, EWSAT1 [28] and EWSAT2 (lnc659). He 
demonstrated that lncRNA EWSAT1 is involved in EWS-
FLI1 mediated gene repression whereas ongoing studies 
are directed at identifying the mechanism of EWSAT2. 
Importantly, knock-down of both lncRNAs interferes with 
tumor cell growth in vitro and in vivo.
TAMING THE MONSTER
To identify vulnerabilities of Ewing sarcoma, 
Kimberly Stegmaier presented the “Pediatric cancer 
dependencies project”, which combines high-throughput 
shRNA and drug screens, super-enhancer profiling, and 
CRISPR/Cas9 mediated knockout on a multitude of 
cell lines in vitro. Using this approach, they identified 
the regulatory subunit of the protein phosphatase PP2A 
complex, STRN4, and the cyclin dependent kinase CDK4 
as essential for Ewing sarcoma cell growth/survival. 
In fact, they found that the CDK4/6 inhibitor LEE011 
(Novartis) has promising in vitro and in vivo cytostatic and 
cytotoxic activity on Ewing sarcoma cells [29]. 
Branka Radic Sarikas performed a synergy screen 
on selected FDA approved drugs and identified synergistic 
cytotoxic effects of IGF1R and protein kinase C inhibition 
in the presence of EWS-FLI1. Kristiina Iljin reported on 
the results of a drugable siRNA cell viability screen in 
an inducible EWS-FLI1 shRNA Ewing sarcoma cell line 
interrogating nearly 7000 genes with 4 siRNAs per gene 
for EWS-FLI1 dependencies, which was performed as part 
of the “ASSET” project. In addition, they also performed 
a small compound screen of >3000 agents comparing 
EWS-FLI1 on/off states in the same model. Integrating 
a variety of genomic data sets and mining the literature 
Kalliopi Tsafou developed an algorithm to link drug 
effects to genes. By this approach, she identified nodes for 
which several drugs scored high in the synthetic lethality 
screen with EWS-FLI1 expression in the Ewing sarcoma 
cell line A673. Among top hits were histone deacetylases. 
Consistent with this finding, Anang Shelat and Elizabeth 
Stewart reported exquisite sensitivity of Ewing sarcoma 
cells to the class I selective HDAC inhibitor OKI-5.
They also reported that adding a poly(ADP-ribose)
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polymerase inhibitor such as Talazoparib or Olaparib 
to Irinotecan and dose-escalating Temozolomide 
yielded approximately 90% survival in Ewing sarcoma 
xenografted mice compared to 100% mortality in mice 
receiving Irinotecan and full-dose Temozolomide. 
Refering to a recently published study, they discussed 
the expression effect of the EWS-FLI1 target SLFN11 
on sensitivity to this drug combination [30]. Synergistic 
activity for combination treatment of patient derived 
xenografts with Olaparib and Trabectedin was reported 
by Enrique de Alava [31]. While PARP1 was previously 
demonstrated to regulate EWS-FLI1 expression and 
transcriptional activity [32], and Trabectidin reported to 
revert the EWS-FLI1 transcriptional signature [33], the 
de Alava study did not detect any effect of the Olaparib 
plus Trabectedin combination on EWS-FLI1 target gene 
expression at Trabectedin concentrations 5-10x lower than 
previously reported to suppress EWS-FLI1.
In addition to targeting hubs in the EWS-ETS 
downstream gene regulatory network , perturbation of the 
expression or functional activity of the gene fusion product 
itself is considered the holy grail from which innovative 
Ewing sarcoma specific therapies may arise. A siRNA 
screen performed in Lee Helman´s lab to identify genes 
whose depletion recapitulates the transcriptional effects 
of EWS-FLI1 knockdown, identified several components 
of the splicing machinery. In fact, knockdown of one 
of them, HNRNPH1, perturbed the correct splicing of 
primary EWS-FLI1 transcripts in cells with breakpoints in 
EWSR1 intron 8 leading to an out-of-frame fusion product. 
An alternative approach to disrupt correct EWS-FLI1 
RNA processing was presented by Marc Ladanyi, who 
showed in vitro data on treatment with splice-switching 
oligonucleotides to introduce premature polyadenylation 
from internal polyA sites of the fusion RNA. In addition, 
Jeff Toretsky´s group recently demonstrated that, in turn, 
altered RNA splicing is one of the EWS-ETS fusion 
protein´s oncogenic functions, which can be inhibited 
by the small molecule YK-4-279 [34]. Jeff Toretsky 
discussed the difficulty of pharmacologically targeting 
the EWS-ETS fusion protein introducing the concept 
of protein concentration dependent physical phase 
separation, potentially nucleated by local enrichment at 
GGAA microsatellites [35]. Although so far all attempts 
to map the exact binding site of the YK-4-279 compound 
along the fusion protein failed, and no influence on the 
EWS-FLI1 transcriptional signature was observed, results 
presented by Lee Helman and Jeff Toretsky encourage 
clinical evaluation of splicing inhibitors in Ewing sarcoma 
patients. 
Alternatively, targeting EWS-ETS protein stability 
may provide a so far unexplored therapeutic option. EWS-
FLI1 stability is regulated by K48 polyubiquitinylation 
and proteasomal degradation. Using a targeted shRNA 
screen interrogating 21 Ewing sarcoma expressed 
deubiquitinating enzymes, Beat Schäfer´s group identified 
ubiquitin-specific protease USP19 as an EWS-FLI1 
regulatory enzyme, whose knockdown destabilizes EWS-
FLI1 protein and may therefore serve as an attractive 
therapeutic target.
Pre-clinical drug validation requires studies in 
model organisms. In the absence of validated rodent 
models for most pediatric cancers, the “Pediatric 
Preclinical Testing Program” (PPTP) studied 67 drugs 
on 83 different xenograft mouse models, in all together 
2134 drug/model comparisons. Peter Houghton reported 
that retrospective analysis of the results for any of 1000 
randomly selected mice accurately predicted the response 
of the whole group in each comparison in 75% of cases. 
The predictive power of the response of a single mouse 
increased to 95%, if one deviation per group was allowed. 
Based on these results, he provocatively suggested to use 
a single mouse xenograft instead of 10 mice per patient 
sample or cell line in future pre-clinical drug efficacy 
tests. This strategy would lower costs and increase 
throughput, two key factors in in vivo drug screens. An 
attractive alternative to mice in this respect are zebrafish. 
James Amatruda presented a chemical suppressor screen 
in a mitfa:EWS-FLI1 transgenic zebrafish model. EWS-
FLI1 is well tolerated by melanocytes which increase 
in number due to oncogene expression. Drug-induced 
reduction in melanocytes can therefore be used as a 
surrogate readout for activity against EWS-FLI1 driven 
cell proliferation. Testing 1200 compounds, they identified 
activity for several kinase inhibitors, bisphosphonates and, 
interestingly, pro-estrogens and anti-androgens.
For an anti-cancer drug to be effective, it needs 
to reach its target via the blood stream. However, about 
50% of tumor vessels are non-functional. Therefore 
normalization of the tumor vasculature should improve 
drug delivery. Keri Schadler reported that vascular shear 
stress, which is induced in endothelial cells by the blood 
flow in response to aerobic exercise, induces functional 
tumor vasculature and increases chemotherapeutic 
efficacy, as exemplified for doxorubicin. She presented 
data identifying a role for nuclear factor of activated 
T cells (NFAT) c1 and thrombospondin TSP1 in the 
normalization of the tumor vasculature.
Whole genome sequencing technologies have 
provided ultimate proof that cancers are vastly different 
from normal tissues and that some of these differences 
will be recognized by the immune system if immune 
checkpoints can be overcome. Identification of 
mechanisms by which tumor cells manipulate the immune 
system is of critical importance for developing strategies 
that reverse tumor-induced immunosuppression and 
sensitize tumor cells to lysis by preexisting or therapeutic 
effector cells. Cellular imunotherapies for Ewing sarcoma 
are under development but have not yet been effective. In 
many cancers, the number of mutations predicts response 
to checkpoint targeting drugs (i.e. anti-PDL1 and -PD1 
antibodies). Since the mutational landscape of Ewing 
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sarcoma is relatively quiet, the question arises if this type 
of cancer is sensitive to immunotherapy. As a first step to 
address this problem, Claudia Rössig reported preliminary 
results on local expression of the immune-inhibitory 
ligand PD-L1 and the non-classical HLA molecule HLA-G 
in the Ewing sarcoma microenvironment, as determined 
by immunohistochemistry in pre-therapy tumor biopsies.
In addition to the EWSR1-ETS gene fusion, Ewing 
sarcoma is characterized by high CD99 expression. Katia 
Scotlandi explored the therapeutic potential of targeting 
this enigmatic surface glycoprotein. She presented new 
results on non-apoptotic tumor cell killing by the murine 
monoclonal antibody O662 and a human, CD99-directed 
single chain antibody. This type of cell death is initiated 
by HRAS and RAC-1 activation and dysregulation of 
micropinocytosis, and is insensitive to overexpression of 
anti-apoptotic Bcl2 family members and ERK activation. 
Dysregulation of RAS signaling in Ewing sarcoma may 
also be deduced from work presented by Florencia Cidre-
Aranaz. She observed EWS-FLI1 mediated suppression 
of the fibroblast growth factor receptor (FGFR) 
antagonist sprouty 1 (SPRY1). FGFR1 has been recently 
demonstrated to be active in Ewing sarcoma [9]. SPRY1 
antagonizes ERK activation of RAS and acts as a tumor 
suppressor in Ewing sarcoma cells reducing proliferation 
and migration when ectopically overexpressed. Florencia 
Cidre-Aranaz reported that increased SPRY1 expression 
was associated with a better relapse-free and overall 
survival, while low SPRY1 levels associated with 
increased metastasis in patients. These data may provide a 
rationale to consider therapeutic use of FGFR1 and RAS 
inhibitors in the treatment of Ewing sarcoma.
PROGRESS SINCE THE FIRST 
INTERDISCIPLINARY EWING 
SARCOMA RESEARCH SUMMIT
In-depth genome and transcriptome sequencing 
studies identified widespread dynamic inter- and intra- 
tumor heterogeneity of Ewing sarcoma down to the single 
cell level. The rapid expansion and spread of sophisticated 
novel next generation sequencing applications beyond 
RNA and genome analysis have provided unprecedented 
insights into chromatin dynamics. Most importantly, it 
has become clear that reprogramming of the epigenome 
and alternative RNA splicing downstream of EWS-
FLI1 play central roles in Ewing sarcoma pathogenesis 
and may therefore provide novel therapeutic targets. 
As the epigenome serves the ultimate “receptor” for 
developmental and microenvironmental signaling 
cues, we have started to understand how tissue context, 
architecture, and metabolic state may influence tumor 
growth with implications for therapy response. For the 
first time, a mouse model of Ewing sarcoma is on the 
horizon based on developmentally tightly timed EWS-
FLI1 expression in the bone mesenchyme, which has the 
potential of speeding-up preclinical drug development in 
the near future.
CONCLUSIONS
Ewing sarcoma remains a monstrous disease to 
patients, families, doctors and scientists. It hatches from 
the malicious activities of EWS-ETS fusion proteins as 
the egg, bred by some neural crest or mesenchyme derived 
stem cell at a defined developmental stage, as parental hen 
and rooster. Researchers at the ASSET/ENCCA meeting 
discussed the role of the soil - the microenvironment, 
and the seed - a susceptible genetic background, which 
are required to feed the chick to become the monster that 
is so difficult to tame. Laboratory data, both mature and 
preliminary, were presented in support of new treatment 
concepts in the war against Ewing sarcoma, including 
the use of epigenetic and specific pathway-directed drugs 
targeting the tumor and its microenvironment (Figure 
1). To enable the next step along the path to clinical 
translation of these promising insights, pre-clinical 
compound testing in animal and/or 3D culture systems, 
it was recognized that the field would greatly benefit 
from an exchange platform to allow for sharing of cell 
lines and models, omic and linked clinical data, standard 
operating procedures and harmonization of protocols. 
The group agreed that the atmosphere of trust, openness 
and cooperativeness demonstrated at this meeting should 
facilitate the establishment of an international working 
group to put in place a common database that keeps 
memory of tested compounds and systems. This would 
be required for efficient prioritization of novel drugs for 
further pre-clinical and clinical development, which may 
hopefully lead to a major transition in the way patients 
with Ewing sarcoma are treated. Such a working group 
should also involve patient advocacy groups in the hope 
that they may help obtain sustained funding sources for 
this endeavor. With their support, ASSET and ENCCA 
tried to pave the way, but with termination of these 
projects in 2016, novel funding strategies are needed to 
keep up the fruitful momentum of the “Second European 
Interdisciplinary Ewing Sarcoma Research Summit”.
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